ArticleCancer cell2019
Venetoclax in Lymphoid Malignancies: New Insights, More to Learn.
Article in Cancer cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- ZMYM3 mutations modulate histone acetylation and cooperate with NOTCH1 mutations in chronic lymphocytic leukemia.Blood advances · 2026Article
- Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation.Cell death & disease · 2024Article
- Article
- Venetoclax Combination Treatment of Acute Myeloid Leukemia in Adolescents and Young Adult Patients.Journal of clinical medicine · 2024Review
- Cyclic peptides discriminate BCL-2 and its clinical mutants from BCL-XNature communications · 2024Article
- MNDA, a PYHIN factor involved in transcriptional regulation and apoptosis control in leukocytes.Frontiers in immunology · 2024Review
- Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies.International journal of molecular sciences · 2023Review
- Dexamethasone enhances venetoclax-induced apoptosis in acute myeloid leukemia cells.Medical oncology (Northwood, London, England) · 2023Article
- Heightened apoptotic priming of vascular cells across tissues and life span predisposes them to cancer therapy-induced toxicities.Science advances · 2022Article
- Progress in understanding the mechanisms of resistance to BCL-2 inhibitors.Experimental hematology & oncology · 2022Review
- A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax.PloS one · 2022Article
- The anti-apoptotic Bcl-2 protein regulates hair follicle stem cell function.EMBO reports · 2021Article
- Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL.Blood advances · 2021Article
- Review of Venetoclax in CLL, AML and Multiple Myeloma.Journal of personalized medicine · 2021Review
- Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.Blood · 2021Article
- Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance.Cell death & disease · 2020Review
- Ancient and conserved functional interplay between Bcl-2 family proteins in the mitochondrial pathway of apoptosis.Science advances · 2020Article
- A genetic predictive model for precision treatment of diffuse large B-cell lymphoma with early progression.Biomarker research · 2020Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this issue of Cancer Cell, Guièza et al. describe that overexpression of the pro-survival protein MCL1 and cellular energy metabolic reprogramming can contribute to resistance to the BCL2 inhibitor venetoclax in patients with chronic lymphocytic leukemia. This adds a new dimension to understanding of secondary clinical resistance to venetoclax.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.